eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 34

Clinical immunology
HLA B27 association in children with juvenile idiopathic arthritis: a clinical study of 72 patients

Yaryna Boyko

Centr Eur J Immunol 2009; 34 (3): 171-175
Online publish date: 2009/09/28
Article file
- HLA B27 association.pdf  [0.08 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Current immunogenetic studies in rheumatology show that different autoimmune diseases are characterized by specific histocompatibility antigens that can be viewed as associated or pathogenetic markers of these diseases. The studies of HLA associations have proved the presence of
a correlation between different histocompatibility antigens and the clinical forms of juvenile idiopathic arthritis (JIA). It has shown the heterogeneity of JIA, which was taken into consideration in the new classification of juvenile arthritis issued at the Congress of The International Antirheumatic League (ILAR) in Durban, 1997, and revised at the following congress in Edmonton, 2001. The International Society of Pediatric Rheumatologists has named juvenile idiopathic arthritis a group of chronic inflammatory diseases of the joints of unknown origin, which last for over 6 weeks in children under 16 years. The Society has distinguished seven categories of the disease [1]. In this classification of JIA (ILAR, 1997-2001), part of juvenile spondyloarthropaties (at the prespondylitic stage) is classified as enthesitis-related arthritis. Psoriatic arthritis is also placed into a separate category with its own diagnostic criteria (definition and exclusion). It is known that the presence of HLA-B27 is one of the diagnostic criteria for not only these two categories of JIA but also for juvenile spondyloarthropathies [2-4]. This heterogenic group of HLA B27-associated inflammatory syndromes includes seronegative enthesopathy with arthropathy (SEA syndrome); juvenile ankylosing spondilitis (AS); ankylosing tarsitis; reactive arthritis (ReA); arthropathies associated with inflammatory diseases of the intestine (Crohn's disease, nonspecific ulcerating colitis) and juvenile psoriatic arthritis [3]. There are 20 subtypes of HLA B27 that have been identified to date (from HLA B27*01 to HLA B27*20). For example, it is known that HLA B27 is the most common in patients with juvenile spondyloarthropathies [5]. Other HLA antigens in different ethnic populations also play an important role in the development of juvenile ankylosing spondilitis (particularly B13, B36, DR3, CW3). Current clinical studies of HLA associations in juvenile idiopathic arthritis are focused on the detection of clinical markers for the disease, which would improve the diagnostics for JIA, and studies of immunogenetic criteria, which would determine the prognosis of the disease.
The purpose of this study was to determine the frequency of HLA B27 association in patients with JIA and to evaluate the clinical peculiarities of arthritis in HLA B27-positive patients.

Material and Methods

The study group included 72 patients with JIA (34 boys, 38 girls) with a mean age at disease onset of 9.5 years. The median disease duration at the time of the study was 3.7 years. A diagnosis of JIA was based on the 1997-2001 ILAR criteria. Clinical evaluation of the type of joint damage included the following criteria: the number and type of the joints involved (small, large or small and large joint damage); symmetry (asymmetry) of arthritis, dactilitis, enthesitis; the presence of back pain; and extraarticular changes.
In 72 children with JIA, the detection of HLA B27 was conducted by use of the flow cytometry method on FACSkan (Becton and Dickinson) with monoclonal anti-HLA B27 antibodies (Becton and Dickinson). The control group included 40 children with reactive arthritis and 17 children that were assessed for other nonrheumatic diseases.
Statistical analysis
The statistical analysis of the results of the study was conducted with “STATISTICA FOR WINDOWS 5.0” (Statsoft, USA). The comparison of parametric data was done with Mann-Whitney criteria as the distribution of the parameter indices in the samples was non-Gaussian (checked according to Shapiro-Wilks criteria). Person's criterion was used to determine the connection between qualitative characteristics (exact Fisher's criteria).


The clinical characteristics of patients with JIA are presented in Table 1. Depending on the HLA B27 results, the patients were divided into 2 groups. The first group included 31 children with positive HLA B27. The second group had 41 patients with negative HLA B27. The first group included 22 (71%) boys; the second had 12 (29.3%) boys. Further studies showed that in the presence of the HLA B27 antigen male children are at significantly higher risk of developing JIA when compared with females (p = 0.0005) (Tab. 2). The mean age at the onset of the disease for the first group was 13.0 years, and for the second group was 6.0 years. It was proved that in the presence of HLA B27 the onset of the disease usually comes at puberty (p = 0.0003).
Among the patients with different clinical types of JIA,
3 (9.7%) children from the first group had polyarthritis,
5 (16.1%) – persistent oligoarthritis, 2 (6.5%) – extended oligoarthritis, 19 (61.3%) – enthesitis-related arthritis, 1 (3.2%) – systemic arthritis and 1 (3.2%) had psoriatic arthritis. In the patients from the second group, the following forms of JIA were detected: polyarthritis in 18 (43.9%) children, persistent oligoarthritis in 15 (36.6%), extended oligoarthritis in
3 (7.3%), systemic in 5 (12.2%), and there were no patients with enthesitis-related arthritis. HLA B27 was a marker for enthesitis-related arthritis (p = 0.0000). For JIA polyarthritis the important marker was the absence of HLA B27 association (p = 0.0017). A large number of children with JIA persistent oligoarthritis were HLA B27 positive (36.6%), although it did not prove to be statistically significant (p = 0.0670).
The studies conducted showed that typical joint damage in children with JIA in the presence of HLA B27 can
be described as asymmetric arthritis of the large joints
(p = 0.0006) with dactilitis (p = 0.0002). Symmetrical arthritis of the small joints or of the large and small joints was shown to be typical for JIA without HLA B27 association (p = 0.0001). Enthesitis was a common finding only in HLA B27-positive children (p = 0.0121).
In patients with reactive arthritis, no statistically significant correlation was found between the presence of HLA B27 and the sex, the mean onset age, or the type of joint damage (Tab. 2). Only the presence of dactilitis was a marker of reactive arthritis in the presence of HLA B27 (p = 0.0167).
The results of a comparative study of the patients with JIA, reactive arthritis, and healthy children showed that HLA B27 association with JIA is statistically significant
(p = 0.0237) (Tab. 3).


The first reports on the association of the MHC class I gene, HLA B27, were published in 1973 for a group of older children with pauciarticular JIA [6]. In the 1980s, Jacobs et al. and Hall et al. reported HLA B27 to be associated with spondyloarthritis and enthesitis in childhood arthritis. The majority of those children were boys, the arthritis involved mainly large joints in the legs, ethesopathy and acute iritis were common. HLA B27 was shown to be associated with the development of sacroiliitis 3-10 years after the onset of the disease [7, 8].
According to Zholobova [9], the distribution of HLA B27 in the general population in Russia constitutes approximately 10% [9]. Hence, the results of this study on the distribution of HLA B27 in the healthy (control) group in Ukraine (11.8%) correspond with previously reported data.
The frequency of HLA B27 association in Ukrainian children with JIA was found to be high – 43.1%. Among 228 patients with juvenile idiopathic arthritis studied in Taiwan, HLA B27 association was revealed in 55.2% [10]. Similar results on the frequency of HLA B27 have been published for groups of patients in Thailand, Korea, and Norway, whereas a low rate of HLA B27 positivity was found in Japan [11-15]. Moe and Rygg suggest that the high proportion of HLA B27 in the JIA population is related to a high prevalence of HLA B27 in the general population [13]. The HLA B27 antigen was found in roughly 16% of the population of Northern Norway, Sweden, and Finland. In two other population-based studies of HLA B27 occurrence in patients with JIA, 28.6% of patients had positive antigen studies in Estonia and 42% in Northern Norway [16, 17]. In a referral center-based study of 680 patients in the USA, 14% were HLA B27 positive and 8% of the controls carried the antigen [18]. It is also interesting that the highest incidence of JIA was reported earlier in Northern Norway where the prevalence of HLA B27 in the general population is high, as is the incidence of AS in adults [19].
Even though the detection of a phenotype cannot be the single diagnostic criterion for JIA, these studies do help to establish a preliminary diagnosis. It was proved in 100% of the cases that the detection of HLA B27 is a marker for the enthesitis-related type of JIA. According to the data in other studies conducted by Packham and Bowness [20] the frequency of HLA B27 in enthesitis-related arthritis is nearly 70% [20].
In this present study, enthesitis-related arthritis was diagnosed in 61.3% of children with a positive HLA B27 marker, and in 26.4% of all the patients with JIA. According to Children's Rheumatology Clinic in Garmisch-Partenkirchen, Germany, nearly 30% of all the children with JIA meet the criteria for enthesitis-related arthritis [21].
There have been three large reviews in the literature with an analysis of the natural history of enthesitis-related arthritis [22-24]. The number of patients included in the two studies [22, 24] was 84 and 55 respectively. Analysis of the data shows a prevalence of males among the patients with enthesitis-related JIA: 73 boys out of 84 patients, 11 boys out of 12 patients, and 17 boys out of 19 patients in this study. The mean onset age in the two studies was 10.5 and 12 ± 2.5 years respectively, which corresponds with the results of the present study – a mean onset age for enthesitis-related arthritis – 13.0 years [22, 23].
Asymmetric arthritis of the large joints was diagnosed in 26 HLA B27-positive patients with JIA, who were included in this study. Mostly, these were patients with enthesitis-related arthritis (19 children), persistent oligoarthritis (5 children) and extended oligoarthritis (2 children). Asymmetrical oligoarthritis was detected in 15 patients with persistent oligoarthritis and in 3 patients with extended oligoarthritis who had negative HLA B27.
The patients with enthesitis-related juvenile arthritis with HLA B27 association are mostly teenaged boys with clinical signs of asymmetric mono- and oligoarthritis of the large joints. In this study, peripheral arthritis usually manifested as mono- or oligoarthritis. The damaged joints were usually the large joints of the legs. At the onset of the disease the knee and ankle joints were damaged the most often (> 70%). In one boy arthritis of the right sterno-clavicular joint was found and proved histologically. In some cases joint damage was observed, especially the hip joint.
In this study, enthesitis was detected only in patients with enthesitis-related JIA. In the study of Li et al., 2003, enthesitis was described in 9 out of 12 children with enthesitis-related arthritis [23]. Wahn et al., 2001, say that 50% of patients with enthesits-related JIA have enthesitis [21]. Leblanc [22], talks about the localization of enthesitis in the patients: the femoral-suprapatellar joint – 17%, the Achilles tendon – 18%, the plantar – 23%, enthesitis having been found in 5 out of 19 children studied (26.3%) [22].
Another typical feature of enthesitis-related arthritis is dactilitis, found in 9 out of 19 patients in current study (47.4%). According to Leblanc [22], dactilitis was found in 15 % of patients, and according to observations conducted by Hafner, dactilitis was found in every third child [22]. Long-term studies conducted for children with enthesitis-related JIA show that half of them develop sacroileitis in the future [20, 25]. Therefore, when conducting a clinical assessment, special attention should be paid to complaints of back pain and any changes which are typical of sacroiliitis that show on X-rays. Back pain was present in 8 out of 19 of children with enthesitis-related JIA but only 2 of them had radiological signs of sacroiliitis (10.5%). According to Leblanc et al., the back pain was present in 13-17% of patients [12]. Flato et al. report radiologically proven sacroileitis in 35% of children with enthesitis-related JIA [24].
Although data reported in the literature shows that 10% to 15% of patients with enthesitis-related arthritis develop uveitis, we did not have any patients with enthesitis-related arthritis who experienced any ophthalmological changes [21].


1. HLA B27 was positive in 43% of the studied patients with JIA.
2. In the presence of HLA B27, boys are at higher risk of developing JIA than girls (p = 0.0005).
3. In the presence of HLA B27 children at puberty (a mean onset age of 13.0 years) have a higher incidence of JIA (p = 0.0003).
4. HLA B27 is an important diagnostic criterion of enthesitis-related arthritis (p = 0, 0000). Asymmetric arthritis of the large joints and enthesitis is a clinical feature of enthesitis-related JIA with positive HLA B27 (p = 0.0006; p = 0.0121).
5. Dactilitis is a diagnostic marker for enthestis-related JIA with positive HLA B27 (p = 0.0002) and reactive arthritis with positive HLA B27 (p = 0.0167).


1. Petty RE, Sounthwood TR, Manners P (2004): International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 31: 390-392.
2. Suschke HJ (1992): Die Behandlung der juvenilen Spondyloarthritis und der reaktiven Arthritis mit Sulfasalazin. Monatsschr Kinderheilkd 140: 658-660.
3. Lee SJ, Im HJ, Schueller WC (2001): HLA B27 positive juvenile arthritis with cardiac involvement preceding sacroiliac joint changes. Heart 86: E19.
4. Kiratiseavee S, Brent HL (2004): Spondyloarthropathies: using presentation to make the diagnosis. Cleveland Clinic J Med 71: 184-205.
5. Burgos-Vargas R (2002): Juvenile onset spondyloarthropathies: therapeutic aspects. Ann Rheum Dis 61: 33-39.
6. Schosstein L, Terasaki P, Bluestone R (1973): High association of an HLA-antigen, w27, with ankylosing spondylitis. N Engl J Med 288: 704-706.
7. Jacobs JC, Berdon WE, Johnston AD (1982): HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observation in 58 patients. J Pediatr 100: 521-528.
8. Hall AM, Burgos Vargos R, Anselle BM (1987): Sacroiliitis in juvenile chronic arthritis. A 10-year follow-up. Clin Exp Rheumatol 5: 65-67.
9. Zholobova YS (2003): Immunogenetic features of juvenile chronic arthritis. Emerging problems of childhood cardiology at VIII Congress of Russian Pediatricians “Current problems of prophylaxis in pediatrics”; pp. 25-30.
10. Wu CJ, Huang JL, Yang MH et al. (2001): Clinical characteristics of juvenile rheumatoid arthritis in Taiwan. J Microbiol Immunol Infect 34: 211-214.
11. Pongpanich B, Daengroongroj P (1988): Juvenile rheumatoid arthritis: clinical characteristics in 100 Thai patients. Clin Rheumatol 7: 257-261.
12. Oh KT, Hong KP, Kim TH et al. (1996): High incidence of HLA-B27 and low incidence of ANA in Korean juvenile rheumatoid arthritis: a descriptive cross-sectional study to analyze profiles related to prognosis. Arthritis Rheum 39 (Suppl): S54.
13. Moe N, Rygg M (1998): Epedemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol 16: 99-101.
14. Fujikawa S, Okuni M (1997): Clinical analysis of 570 cases with juvenile rheumatoid arthritis: results of a nationwide retrospective survey in Japan. Acta Paediatr Jpn 39: 245-249.
15. Huang JL, Chen LC (1988): Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 17: 359-363.
16. Pruunsild C, Uibo K, Liivamägi H (2007): Incidence of juvenile idiopathic arthritis in children in Estonia: a prospective population-based study. Scand J Rheumatol 36: 7-13.
17. Berntson L, Damga°rd M, Andersson-Gäre B (2008): HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol 35: 2055-2061.
18. Murray KJ, Moroldo MB, Donnelly P (1999): Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. Arthritis Rheum 42: 1843-1853.
19. Bakland G, Nossent HC, Gran JT (2005): Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Rheum 53: 850-855.
20. Packham JC, Bowness P (2001): Seronegative Spondyloarthropathies. Arthritis Res Campaigh 4: 26-32.
21. Wahn V, Oppermann J, Huppertz HI (2001): Rheumatische Erkrankungen im Kindes und Jugendalter; p. 672.
22. Leblanc CM, Feldman BM, Laxer RM (2003): Enthesitis-related arthritis: clinical, laboratory and radiographic features at presentation in a large single institution cohort. Pediatric Rheumatol Online J http://www.pedrheumonlinejournal.org/June/151.htm
23. Li CW, Hu J, Pi SH (2003): Clinical characteristics of children with enthesitis-related arthritis. Zhonghua Er Ke Za Zhi 41: 835-838.
24. Flato B, Hoffman-Vold AM, Reiff A (2006): Long-term outcome and prognostic factors in enthesitis-related arthritis: a case
– control study. Arthr Rheum 54: 3573-3582.
25. Huppertz HI (2002): Oligoarthritis im Kinders und Jugendalter. Monatsschift Kinderheilkunde 150: 437-444.
Copyright: © 2009 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe